ROCKVILLE, Md., Dec. 2, 2024 (GLOBE NEWSWIRE) – OncoC4, a late-stage clinical biopharmaceutical company focused on developing new therapies for cancer and neurological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its AI-081 project. AI-081 is a best-in-class bispecific antibody targeting PD-1 and VEGF, designed for the potential treatment of advanced solid tumors. Upon receiving the FDA’s Study May Proceed Letter, OncoC4 anticipates initiating the Phase 1/2 clinical trial, BIPAVE-001, in the first quarter of 2025 to evaluate AI-081 in patients with advanced solid tumors.
